Enrico P. Veltri, a Schering-Plough vice-president who played the central role in a controversial study of the cholesterol drug Vytorin, has left the company following its acquisition by Merck.
"Since the merger, Rick has consulted for the company," Merck said in a statement. Veltri is listed as an independent consultant in his role as the industry representative on a panel being held by the Food and Drug Administration to examine the safety of GlaxoSmithKline's diabetes drug Avandia.
via blogs.forbes.com
Matt Herper dishes it!
No comments:
Post a Comment